Pfizer lung cancer drug promising in early tests

Jun 05, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- It's way too soon to declare success, but an experimental drug for lung cancer patients with a certain gene showed extraordinary promise in early testing, doctors reported at a cancer conference on Saturday.

More than 90 percent of the 82 patients in a study saw their tumors shrink after two months on the drug, Pfizer Inc.'s crizotinib, (crih-ZAH-tin-ib), researchers reported.

Doctors had expected only about 10 percent of these very sick patients to respond to the drug, according to one of the study's leaders, Dr. Yung-Jue Bang of the Seoul National University College of Medicine in South Korea.

These were people with advanced disease, including some whose cancers had spread to the brain. They had already tried an average of three other drugs. Responses to crizotinib have lasted up to 15 months so far, and the drug has been rushed into late-stage testing, Bang said.

Many leading cancer specialists, who normally don't get excited until a drug proves effective in large studies against existing treatments, said the research so far on crizotinib was promising.

"It's early, but I'm impressed by it. It looks extremely effective," said Dr. Roy Herbst, chief at the University of Texas M.D. Anderson Cancer Center in Houston. He has consulted for makers of other lung but not this one.

Dr. Alice Shaw, the Massachusetts General Hospital doctor who is leading a larger study of crizotinib, agreed.

"I don't think there is false hope. The data are so strong," she said.

The drug targets a gene that promotes tumor growth and is found in about 4 percent of lung cancers, especially among younger, non-smokers. This small percentage is still a lot of people: nearly 220,000 new cases of lung cancer are diagnosed each year in the United States alone, and it is the world's top cancer killer.

That means that up to 10,000 people in the U.S. annually could benefit, said Dr. Mark Kris, a lung cancer specialist at Memorial Sloan-Kettering Cancer Center in New York, who has consulted for Pfizer.

Two other gene-targeted treatments, Tarceva and Iressa, help about 20,000 lung cancer patients annually in the U.S.

"We're chipping away at large numbers of patients," and future gene discoveries should add to the number helped, Herbst said.

The gene targeted by crizotinib was discovered in 2007, Kris noted.

"Once we understand a cancer cell, we can come up with a treatment very quickly," he said.

No show-stopping side effects were seen in the first study - half of patients on crizotinib had diarrhea, nausea or vomiting - but much larger tests are needed to establish safety.

Even more testing is needed to see if the drug is more effective than existing treatments, how long any benefits last, and whether it improves survival - not just shrinks tumors.

sponsored the study and has already launched bigger studies to compare crizotinib to current standard treatments. The company hopes to seek federal Food and Drug Administration approval for the drug next year.

The study was presented Saturday at a meeting in Chicago of the American Society of Clinical Oncology.

Explore further: Cancer patients need anxiety, depression screening

More information: Cancer meeting: http://www.asco.org
National Cancer Institute: http://www.cancer.gov
Pfizer: http://www.pfizer.com

4.1 /5 (11 votes)
add to favorites email to friend print save as pdf

Related Stories

Researchers develop new method to test for lung cancer

Apr 01, 2008

Researchers from Boston University School of Medicine have developed a new “clinicogenomic model” to accurately test for lung cancer. The model combines a specific gene expression for lung cancer as well as clinical ...

Recommended for you

Cancer patients need anxiety, depression screening

7 hours ago

(HealthDay)—It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published online April 14 in the Journal of Clinical Oncology.

Pre-HPV vaccine, most oropharyngeal cancers HPV+

9 hours ago

(HealthDay)—Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus (HPV), specifically HPV 16 or 18, according to a study published in the May issue of the ...

'Dustman' protein helps bin cancer cells

Apr 21, 2014

Cancer researchers have discovered a new 'dustman' role for a molecule that helps a drug kill cancer cells according to a study, published in the journal Proceedings of the National Academy of Sciences (PNAS) ...

User comments : 0

More news stories

Volitional control from optical signals

(Medical Xpress)—In their quest to build better BMIs, or brain-machine-interfaces, researchers have recently begun to look closer at the sub-threshold activity of neurons. The reason for this trend is that ...

Neuroimaging: Live from inside the cell

A novel imaging technique provides insights into the role of redox signaling and reactive oxygen species in living neurons, in real time. Scientists of the Technische Universität München and the Ludwig-Maximilians-Universität ...

Mantis shrimp stronger than airplanes

(Phys.org) —Inspired by the fist-like club of a mantis shrimp, a team of researchers led by University of California, Riverside, in collaboration with University of Southern California and Purdue University, ...